Overview

Ebola Vaccines and Drugs Market is poised to value over USD xx billion by 2027 end at a CAGR of over xx% during the forecast period 2020 to 2027.

The development of management protocols pertaining to Ebola virus is one of the important factors responsible for the growth of the market due to the unmet needs of the discovery of a cure for the virus. Furthermore, the government is consistently supporting research for treating Ebola virus by developing vaccines and drugs which has also proven to be a lucrative opportunity for pharmaceutical companies to expand their businesses globally.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Ebola Vaccines and Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Ebola Vaccines and Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Ebola Vaccines and Drugs Market:

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services, Inc.
• Hemispherx Biopharma, Inc.
• BioCryst Pharmaceuticals, Inc.
• NanoViricides, Inc.
• NewLink Genetics Corporation
• Chimerix, Inc.
• Sarepta Therapeutics
• Mapp Biopharmaceutical, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Ebola Vaccines and Drugs Market Segmentation:

By Treatment

• Vaccine (Under Trials)
• cAd3-Zebov
• rVSV-Zebov
• TKMEbola
• AVI-7537
• HEB
• BCRX
• NNVC
• Drugs (Under Trials)
• Brincidofovir
• ZMapp
• Favipiravir
• Zoloft
• Vascor

By End User

• Hospitals
• Ambulatory Surgery Centres
• Specialized Clinics
• Army Camps (Veteran Facilities)  

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Ebola Vaccines and Drugs Market By Treatment, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
       1.1 Objectives of the Study 
       1.2 Market Definition 
       1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
       1.4 Currency 
       1.5 Limitations 
       1.6 Stakeholders 

 2.  Research Methodology 
       2.1 Research Data 
              2.1.1 Secondary Data
                 2.1.1.1 Key Data from Secondary Sources
              2.1.2 Primary Data
                 2.1.2.1 Key Data from Primary Sources
       2.2 Market Size Estimation 
       2.3 Market Breakdown and Data Triangulation 
       2.4 Assumptions for the Study  

3. Executive Summary
       3.1 Market Outlook
       3.2 Segment Outlook
       3.3 Competitive Insights

4. Global Ebola Vaccines and Drugs Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances

5. Market Overview
       5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Ebola Vaccines and Drugs Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Ebola Vaccines and Drugs Market Analysis Tools
       6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
       6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
       6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
       6.4. Market Entry Strategies
       6.5. Case Studies

7. Global Ebola Vaccines and Drugs Market, By Treatment Historical Analysis and Forecast 2020-2027 (USD Million)
       7.1. Vaccine (Under Trials)
              7.1.1. cAd3-Zebov
              7.1.2. rVSV-Zebov
              7.1.3. TKMEbola
              7.1.4. AVI-7537
              7.1.5. HEB
              7.1.6. BCRX
              7.1.7. NNVC
       7.2. Drugs (Under Trials)
              7.2.1. Brincidofovir
              7.2.2. ZMapp
              7.2.3. Favipiravir
              7.2.4. Zoloft
              7.2.5. Vascor 

8. Global Ebola Vaccines and Drugs Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
       8.1. Hospitals
       8.2. Ambulatory Surgery Centres
       8.3. Specialized Clinics
       8.4. Army Camps (Veteran Facilities)

9.  North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       9.1. Introduction
       9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            9.2.1. U.S.A
            9.2.2. Canada
            9.2.3. Mexico
       9.3. Market Size (USD Million) Forecast for North America 2020-2027

10. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       10.1. Introduction
       10.2. Regional Market Trends
       10.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            10.3.1. Brazil
            10.3.2. Venezuela
            10.3.3. Argentina
            10.3.4. Rest of Latin America
       10.4. Market Size (USD Million) Forecast for Latin America 2020-2027

11. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       11.1. Introduction
       11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            11.2.1. Germany
            11.2.2. U.K
            11.2.3. France
            11.2.4. Italy
            11.2.5. Spain
            11.2.6. Russia
            11.2.7. Poland
            11.2.8. Switzerland
            11.2.9. Rest of Western Europe

12. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       12.1. Introduction
       12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             12.2.1. Japan
             12.2.2. China
             12.2.3. Singapore
             12.2.4. India
             12.2.5. Australia and New Zealand
             12.2.6. ASEAN
             12.2.7. South Korea
             12.2.8. Rest of Asia Pacific
       12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       13.1. Introduction
       13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             13.2.1. Saudi Arabia
             13.2.2. UAE
             13.2.3. South Africa
             13.2.4. Egypt
       13.3. Market Size (USD Million) Forecast for MEA 2020-2027

14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts)
       14.1. Arbutus Biopharma
                14.1.1. Company Overview
                14.1.2. Product Portfolio
                14.1.3. SWOT Analysis
                14.1.4. Financial Overview
                14.1.5. Strategic Overview
       14.2. GlaxoSmithKline
                14.2.1. Company Overview
                14.2.2. Product Portfolio
                14.2.3. SWOT Analysis
                14.2.4. Financial Overview
                14.2.5. Strategic Overview
       14.3. Johnson & Johnson Services, Inc.
                14.3.1. Company Overview
                14.3.2. Product Portfolio
                14.3.3. SWOT Analysis
                14.3.4. Financial Overview
                14.3.5. Strategic Overview
       14.4. Hemispherx Biopharma, Inc.
                14.4.1. Company Overview
                14.4.2. Product Portfolio
                14.4.3. SWOT Analysis
                14.4.4. Financial Overview
                14.4.5. Strategic Overview
       14.5. BioCryst Pharmaceuticals, Inc.
                14.5.1. Company Overview
                14.5.2. Product Portfolio
                14.5.3. SWOT Analysis
                14.5.4. Financial Overview
                14.5.5. Strategic Overview
       14.6. NanoViricides, Inc.
                14.6.1. Company Overview
                14.6.2. Product Portfolio
                14.6.3. SWOT Analysis
                14.6.4. Financial Overview
                14.6.5. Strategic Overview
       14.7. NewLink Genetics Corporation
                14.7.1. Company Overview
                14.7.2. Product Portfolio
                14.7.3. SWOT Analysis
                14.7.4. Financial Overview
                14.7.5. Strategic Overview
       14.8. Chimerix, Inc.
                14.8.1. Company Overview
                14.8.2. Product Portfolio
                14.8.3. SWOT Analysis
                14.8.4. Financial Overview
                14.8.5. Strategic Overview
       14.9. Sarepta Therapeutics
                14.9.1. Company Overview
                14.9.2. Product Portfolio
                14.9.3. SWOT Analysis
                14.9.4. Financial Overview
                14.9.5. Strategic Overview
       14.10. Mapp Biopharmaceutical, Inc.
                14.10.1. Company Overview
                14.10.2. Product Portfolio
                14.10.3. SWOT Analysis
                14.10.4. Financial Overview
                14.10.5. Strategic Overview
       
15. FutureWise SME key takeaway points for Client

Tables

Figures